Most conversations about biomanufacturing begin and end with cultured meat, as if the only relevant product of this technology were slaughter-free hamburgers. This radically underestimates what is happening. Biofabrication is a fundamental reconfiguration of manufacturing logic—the idea that living organisms can be programmed to produce materials, compounds, and structures with precision and scale that conventional chemical or mechanical processes cannot achieve.
What exactly is biofabrication
Biomanufacturing uses biological systems — bacteria, yeast, fungi, animal or plant cells — as production agents. The difference from traditional biotechnology is not just one of degree; It's a mental model. In classical biotechnology, an organism is modified to produce a specific medicine. In biomanufacturing, the organism is the factory: you design the production process at a genetic and metabolic level, and the living being executes it.
Spider silk is an elegant example of the difference. Spider silk protein is extraordinarily tough—by weight, stronger than steel—but spiders cannot be bred in captivity at scale. Biomanufacturing solves this by inserting the genes responsible for producing the protein into yeast, which ferment in bioreactors and secrete silk. Bolt Threads does just that and already supplies fashion brands like Stella McCartney. The material is not synthetic in the conventional sense, but it does not require spiders either: it is a third category.
Where technology is already working
Cultured meat gets attention disproportionately for the emotional impact of the idea, but the challenges of scale are real: cost per kilogram is still high, texture of complex cuts remains an engineering problem, and regulation is nascent. Singapore was the first country to approve commercialization in 2020. The United States approved it in 2023. Brazil does not yet have a defined regulatory framework.
Much more advanced on a commercial scale are materials based on mycelium — the fungus' network of filaments. Companies like Ecovative and Mogu use mycelium to create structural packaging that replaces Styrofoam, construction panels and even leather. The process is simple: agricultural substrate is mixed with spores, the mycelium colonizes the material within days, and the resulting structure can be molded into any shape before being dried to stop growth. The cost is already competitive with petrochemical alternatives in some applications.
Precision fermentation is perhaps the field with the most immediate traction. Uses edited microorganisms to produce specific proteins — cow-free casein and milk protein, bovine blood-free hemoglobin, animal-free collagen. Companies like Perfect Day and Remilk already sell milk protein produced through fermentation to food manufacturers. The final product is chemically identical to the animal, without the overhead of breeding, slaughtering and cold chain.
Sectoral implications beyond the green narrative
The most common strategic mistake when analyzing biomanufacturing is treating it as a sustainability solution — a "greener" alternative to what already exists. This captures part of the story, but ignores the most important part: biomanufacturing changes the cost structure, the geography of production, and the barriers to entry of entire industries.
In fashion and textile materials, mycelium leather and fermented silk enable local production on a relatively small scale without relying on global animal or petrochemical supply chains. This reverses decades of offshoring logic in the industry. A company that controls the genetic design of the process can produce the material where the customer is, with customized variations that would be impossible in conventional processes.
In pharmacy and healthcare, biomanufacturing is already an established reality for insulin, hormones and monoclonal antibodies. What changes is the expansion of this model to medical materials, scaffolds for tissue engineering and, on the horizon, organs for transplantation — biofabrication not just of molecules, but of functional three-dimensional structures.
In packaging and industrial materials, competition with plastics and petrochemicals still depends on cost parity that some applications have already achieved and others will achieve as synthetic biology makes gene editing tools cheaper and bioreactors become more efficient.
How a leader should look at this
Biofabrication is not a technology to monitor from a comfortable distance. For the processed food, fashion, packaging, building materials and pharmaceutical sectors, it represents pressure that will make entire parts of the value chain uneconomical before most incumbents have finished studying the issue — and a repositioning opportunity for the first mover.
The relevant strategic question is not “should I invest in biomanufacturing?” — for most companies, the answer is no, at least not directly in agency R&D. The right question is: which of my critical inputs or value propositions can be replaced or radically altered by biofabricated products? And who, among my suppliers or competitors, is already testing this replacement?
The planning horizon matters here. In the short term — two to three years — the impacts are concentrated in niches: premium products, markets with favorable regulation, applications where the technical benefit outweighs the additional cost. In the medium term, as costs fall and regulation matures, penetration into mass markets begins. Companies that wait to see scale before acting will find the adoption curve steeper than they expected.
The most useful parallel is with solar energy: for years it was treated as an expensive niche and not very relevant to conventional infrastructure decisions. When the cost crossed the competitiveness threshold, the speed of adoption surprised just about everyone. Biofabrication is following a similar trajectory, with the advantage that synthetic biology is becoming more programmable and cheaper with each innovation cycle.
Also read
- How to build a business case for AI in industrial operations
- Gene editing as infrastructure: what CRISPR means for industry
- Precision fermentation: animal-free animal proteins
- Industrial IoT in practice: what separates pilot projects from full scale
- Materials of the future: what will replace plastic in the next decade
- Alternative protein: What food companies need to decide now